scholarly journals Understanding Benefits of Curcumin on Cognitive Function from Molecular Aspect: A Review

2021 ◽  
pp. 1-7
Author(s):  
A. A. A. Putri Laksmidewi ◽  
Richard Suherlim
Keyword(s):  
Cognitive Function ◽  
Cognitive Decline ◽  
Low Grade ◽  
Molecular Aspect ◽  
Amyloid Aggregation ◽  
Neuroprotective Effects ◽  
Aggregation Inhibition ◽  
Β Amyloid ◽  
Over Time

Cognitive function has a significant impact on individuals’ quality of life. Over time, human cognitive function tends to decline. The importance of cognitive function in everyday life has led many researchers to seek alternative treatments to maintain and improve cognitive function. Some studies show that curcumin can improve cognitive function and prevent cognitive decline in humans.  This review focuses on the benefits of curcumin on cognitive function and the mechanism of how it works from molecular aspect. According to some studies, one of the factors leading to cognitive decline is chronic low-grade systemic inflammation. This review will focus on antioxidant, anti-inflammatory, neuroprotective effects, and β amyloid aggregation inhibition properties of curcumin that can improve cognitive function or delay cognitive decline. It is important to understand the basic reasons why curcumin can have benefits on cognitive function, this can be seen from the mechanisms that are reflected in the biomolecular aspect.

scholarly journals Evaluation of the effect of Cooled HaEmodialysis on Cognitive function in patients suffering with end-stage KidnEy Disease (E-CHECKED): feasibility randomised control trial protocol

Trials ◽  
2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Indranil Dasgupta ◽  
Aghogho Odudu ◽  
Jyoti Baharani ◽  
Niall Fergusson ◽  
Helen Griffiths ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cognitive Function ◽  
Cognitive Decline ◽  
Feasibility Trial ◽  
Cognitive Test ◽  
Randomised Control Trial ◽  
Secondary Outcome ◽  
Dialysis Fluid ◽  
Dialysate Temperature

Abstract Background Cognitive impairment is common in haemodialysis (HD) patients and is associated independently with depression and mortality. This association is poorly understood, and no intervention is proven to slow cognitive decline. There is evidence that cooler dialysis fluid (dialysate) may slow white matter changes in the brain, but no study has investigated the effect of cooler dialysate on cognition. This study addresses whether cooler dialysate can prevent the decline in cognition and improve quality of life (QOL) in HD patients. Methods This is a multi-site prospective randomised, double-blinded feasibility trial. Setting: Four HD units in the UK. Participants and interventions: Ninety HD patients randomised (1:1) to standard care (dialysate temperature 36.5 °C) or intervention (dialysate temperature 35 °C) for 12 months. Primary outcome measure: Change in cognition using the Montreal Cognitive Assessment (MoCA). Secondary outcome measures: Recruitment and attrition rates, reasons for non-recruitment, frequency of intradialytic hypotension, depressive symptom scores, patient and carers burden, a detailed computerised cognitive test and QOL assessments. Analysis: mixed method approach, utilising measurement of cognition, questionnaires, physiological measurements and semi-structured interviews. Discussion The results of this feasibility trial will inform the design of a future adequately powered substantive trial investigating the effect of dialysate cooling on prevention and/or slowing in cognitive decline in patients undergoing haemodialysis using a computerised battery of neuro-cognitive tests. The main hypothesis that would be tested in this future trial is that patients treated with regular conventional haemodialysis will have a lesser decline in cognitive function and a better quality of life over 1 year by using cooler dialysis fluid at 35 °C, versus a standard dialysis fluid temperature of 36.5 °C. This also should reflect in improvements in their abilities for activities of daily living and therefore reduce carers’ burden. If successful, the treatment could be universally applied at no extra cost. Trial registration ClinicalTrials.gov NCT03645733. Registered retrospectively on 24 August 2018.

scholarly journals The association of health-related quality of life and cognitive function in patients receiving memantine for the prevention of cognitive dysfunction during whole-brain radiotherapy

2018 ◽  
Vol 6 (4) ◽  
pp. 274-282 ◽  
Author(s):  
Nadia N Laack ◽  
Stephanie L Pugh ◽  
Paul D Brown ◽  
Sherry Fox ◽  
Jeffrey S Wefel ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cognitive Function ◽  
Brain Metastases ◽  
Whole Brain Radiotherapy ◽  
Health Related Quality ◽  
Brain Radiotherapy ◽  
Related Quality ◽  
Health Related ◽  
Over Time

Abstract Background This study evaluated the association between health-related quality of life (HRQOL) and cognition in patients receiving memantine for prevention of cognitive dysfunction during whole-brain radiotherapy (WBRT). Methods Adult patients with brain metastases received WBRT and were randomized to receive placebo or memantine, 20 mg per day, within 3 days of initiating radiotherapy, for 24 weeks. The Functional Assessment of Cancer Therapy-Brain module (FACT-Br) and Medical Outcomes Scale-Cognitive Functioning Scale (MOS-C) were completed in coordination with serial standardized tests of cognitive function. Results Of the 508 eligible patients, 442 (87%) consented to participate in the HRQOL portion and contributed to baseline analyses. Evaluable patients at 24 weeks (n = 246) included surviving patients completing FACT-Br, MOS-C, and objective cognitive assessments (n = 146, 59%) and patients alive at time of missed assessment (n = 100, 41%). Baseline cognitive function correlated significantly with FACT-Br and MOS-C self-reports. All domains of objective cognitive function showed declines over time. Neither FACT-Br nor MOS-C differed between the treatment arms. Emotional and functional well-being subscales of the FACT improved over time while the remainder of the FACT-Br domains remained stable. MOS-C scores declined over time. Conclusion Baseline cognitive function correlated significantly with FACT-Br and MOS-C scores. No by-arm differences in HRQOL were observed despite differences in objective cognitive function. Patient attrition and poor testing compliance remain significant problems in studies of cognitive function of brain metastases patients and further effort is needed to improve compliance with testing and sensitivity of patient-reported measures.

scholarly journals The Link Between Physical Activity and Cognitive Dysfunction in Alzheimer Disease

2015 ◽  
Vol 95 (7) ◽  
pp. 1046-1060 ◽  
Author(s):  
Cristy Phillips ◽  
Mehmet Akif Baktir ◽  
Devsmita Das ◽  
Bill Lin ◽  
Ahmad Salehi
Keyword(s):  
Physical Activity ◽  
Cognitive Function ◽  
Alzheimer Disease ◽  
Cognitive Decline ◽  
Cognitive Dysfunction ◽  
Physical Therapist ◽  
Disease Process ◽  
Sufficient Evidence ◽  
Brain Disorder ◽  
Neuroprotective Effects

Alzheimer disease (AD) is a primary cause of cognitive dysfunction in the elderly population worldwide. Despite the allocation of enormous amounts of funding and resources to studying this brain disorder, there are no effective pharmacological treatments for reducing the severity of pathology and restoring cognitive function in affected people. Recent reports on the failure of multiple clinical trials for AD have highlighted the need to diversify further the search for new therapeutic strategies for cognitive dysfunction. Thus, studies detailing the neuroprotective effects of physical activity (PA) on the brain in AD were reviewed, and mechanisms by which PA might mitigate AD-related cognitive decline were explored. A MEDLINE database search was used to generate a list of studies conducted between January 2007 and September 2014 (n=394). These studies, along with key references, were screened to identify those that assessed the effects of PA on AD-related biomarkers and cognitive function. The search was not limited on the basis of intensity, frequency, duration, or mode of activity. However, studies in which PA was combined with another intervention (eg, diet, pharmacotherapeutics, ovariectomy, cognitive training, behavioral therapy), and studies not written in English were excluded. Thirty-eight animal and human studies met entry criteria. Most of the studies suggested that PA attenuates neuropathology and positively affects cognitive function in AD. Although the literature lacked sufficient evidence to support precise PA guidelines, convergent evidence does suggest that the incorporation of regular PA into daily routines mitigates AD-related symptoms, especially when deployed earlier in the disease process. Here the protocols used to alter the progression of AD-related neuropathology and cognitive decline are highlighted, and the implications for physical therapist practice are discussed.

scholarly journals Recurrent delirium over 12 months predicts dementia: results of the Delirium and Cognitive Impact in Dementia (DECIDE) study

2020 ◽  
Author(s):  
Sarah J Richardson ◽  
Daniel H J Davis ◽  
Blossom C M Stephan ◽  
Louise Robinson ◽  
Carol Brayne ◽  
...  
Keyword(s):  
Cognitive Function ◽  
Cognitive Decline ◽  
Hospital Admissions ◽  
Outcome Data ◽  
Illness Severity ◽  
Cognitive Outcomes ◽  
Dementia Diagnosis ◽  
Increased Risk ◽  
The Impact ◽  
Over Time

Abstract Background Delirium is common, distressing and associated with poor outcomes. Previous studies investigating the impact of delirium on cognitive outcomes have been limited by incomplete ascertainment of baseline cognition or lack of prospective delirium assessments. This study quantified the association between delirium and cognitive function over time by prospectively ascertaining delirium in a cohort aged ≥ 65 years in whom baseline cognition had previously been established. Methods For 12 months, we assessed participants from the Cognitive Function and Ageing Study II-Newcastle for delirium daily during hospital admissions. At 1-year, we assessed cognitive decline and dementia in those with and without delirium. We evaluated the effect of delirium (including its duration and number of episodes) on cognitive function over time, independently of baseline cognition and illness severity. Results Eighty two of 205 participants recruited developed delirium in hospital (40%). One-year outcome data were available for 173 participants: 18 had a new dementia diagnosis, 38 had died. Delirium was associated with cognitive decline (−1.8 Mini-Mental State Examination points [95% CI –3.5 to –0.2]) and an increased risk of new dementia diagnosis at follow up (OR 8.8 [95% CI 1.9–41.4]). More than one episode and more days with delirium (>5 days) were associated with worse cognitive outcomes. Conclusions Delirium increases risk of future cognitive decline and dementia, independent of illness severity and baseline cognition, with more episodes associated with worse cognitive outcomes. Given that delirium has been shown to be preventable in some cases, we propose that delirium is a potentially modifiable risk factor for dementia.

Association of Sleep Disturbances and Cognitive Decline among Cognitively Normal Elders Over Time (Preprint)

2021 ◽  
Author(s):  
Xiuhua Guo ◽  
Mandela William Nzoyoum Kuetche ◽  
Meng Zhang ◽  
Mengmeng Liu ◽  
Yue Liu ◽  
...  
Keyword(s):  
Cognitive Function ◽  
Cognitive Decline ◽  
Regression Models ◽  
Sleep Disturbances ◽  
Marginal Effect ◽  
Amyloid Pet ◽  
Longitudinal Impact ◽  
Cognitively Normal ◽  
Cox Regression Analysis ◽  
Over Time

BACKGROUND While sleep disturbances (SD) has been shown to be associated with worse cognition, but the causal relationship between the two subjects to debate. Our objective was to investigate the longitudinal impact of SD on cognitive function. OBJECTIVE To determine the effect of self-reported clinical diagnosis of SD on longitudinal changes in brain amyloid-PET, CSF-biomarkers (Aβ42, T-tau and P-tau) and cognitive function in cognitively normal. METHODS A total of 463 cognitively normal elders (357 normal and 106 SD) were included. Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants were collected from 2005 to 2020. The generalized linear mixed models adjusting variables which were selected by the Akaike Information Criterion (AIC) and the marginal effect estimation method was used to estimate the risk effect of SD. Cox proportional hazards regression models estimated the relative hazard of AD, among baseline SD patients. RESULTS The age range of participants was 73.60±5.71 years old, and the female proportion was 43.63%. In adjusted regression models, Participants with baseline SD had higher likelihood of developing worse cognition over subsequent follow-up, PACC (decrease 7.53 points [95%CI, 7.36-7.70]; P<0.001), MMSE (decrease 5.26 points [95%CI, 5.17-5.35]; P<0.001), and CDR–Sum of Boxes (increase 5.61 points [95%CI, 5.67-5.54]; P=0.001). Similarly, Cox regression analysis suggested that sleep disturbances is a risk factor of AD (HR=1.55, 95% CI=1.08 to 2.22). CONCLUSIONS SD probably is a warning sign of AD, because it is associated with greater likelihood of cognitive decline or dementia over time. Associations are likely multifactorial and could be explained by intervening variables in the path from SD to dementia, or by common risk factors for pathological processes in brain. These findings suggest need for more attentions of older adults with sleep compromise.

OS09.4.A Health-related quality of life in low-grade glioma survivors 26 years after diagnosis

2021 ◽  
Vol 23 (Supplement_2) ◽  
pp. ii12-ii12
Author(s):  
F W Boele ◽  
J C Reijneveld ◽  
P C de Witt Hamer ◽  
H F van Thuijl ◽  
P Wesseling ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Low Grade ◽  
Group Level ◽  
Related Quality ◽  
Health Related ◽  
Changes Over Time ◽  
Over Time

Abstract BACKGROUND Many patients with low-grade gliomas (LGGs) continue to survive for many years, yet little is known about patients’ health-related quality of life (HRQOL) in long-term survivorship. We previously investigated HRQOL in LGG patients diagnosed on average 6 years prior to assessment (T1, N=195) with a follow-up in stable patients on average 12 years after diagnosis (T2, N=65). We present a final follow-up of LGG survivors (T3), now decades after diagnosis. MATERIAL AND METHODS We invited patients who participated in our previous assessment (N=65), regardless of disease status. Patients completed questionnaires to assess HRQOL, fatigue, and depressive symptoms: Short Form-36 Health Survey (SF-36), European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Brain Tumour Module (EORTC BN20), Checklist Individual Strength (CIS), and the Center for Epidemiological Studies Depression Scale (CES-D). Changes over time (T1-T2-T3) on group level and participant level were assessed. RESULTS Of the 65 patients, 18 (27.7%) were deceased, 3 (4.6%) experienced tumour progression to WHO III, 7 (10.8%) declined, and 3 (4.6%) could not be contacted. Thirty-four patients (52.3%) participated. Of these, 2 had missing HRQOL data, with 32 patients included in analysis. Survivors were M=52.0 (sd=11.3) years old and diagnosed M=26.2 (sd=3.7, range 19–35) years prior. On group level, a statistically significant (but not clinically relevant) improvement in mental health (p=0.049), and a clinically relevant (but not statistically significant) decline in emotional role functioning was found. No other group-level changes over time in HRQOL were found. Minimal detectable change in HRQOL scale scores over time was observed in individual participants (28.1% only improvement; 25.0% only decline; 21.9% both improvement and decline) with 25.0% remaining completely stable. At T3, 25.0% of survivors scored above the cut-off for high risk of clinical depression (≥16 CES-D), and 53.1% of survivors classed as severely fatigued (≥35 CIS). CONCLUSION In this cohort of LGG survivors, assessed decades after diagnosis and treatment, HRQOL does not appear to be greatly impacted during survivorship. However, depressive symptoms and fatigue remain relatively common. Findings can help inform patients, their families, and clinicians and can serve as a benchmark for treatment trials evaluating interventions that can have very long-term effects.

N-1,2,3-triazole-isatin derivatives for cholinesterase and β-amyloid aggregation inhibition: A comprehensive bioassay study

2020 ◽  
Vol 98 ◽  
pp. 103753 ◽  
Author(s):  
Carolina S. Marques ◽  
Óscar López ◽  
Donatella Bagetta ◽  
Elisabete P. Carreiro ◽  
Sabrina Petralla ◽  
...  
Keyword(s):  
Amyloid Aggregation ◽  
Aggregation Inhibition ◽  
Β Amyloid ◽  
Isatin Derivatives

scholarly journals The Association Between the Changes in General, Family, and Financial Aspects of Quality of Life and Their Effects on Cognitive Function in an Elderly Population: The Korean Longitudinal Study of Aging, 2008–2016

2020 ◽  
Vol 17 (3) ◽  
pp. 1106 ◽  
Author(s):  
Wonjeong Chae ◽  
Eun-Cheol Park ◽  
Sung-In Jang
Keyword(s):  
Quality Of Life ◽  
Older Adults ◽  
Longitudinal Study ◽  
Cognitive Function ◽  
Cognitive Decline ◽  
Elderly Population ◽  
Equation Model ◽  
Cognitive Changes ◽  
Korean Elderly

Background The growing aging population is a global phenomenon and a major public health challenge. Among Organization for Economic Co-operation and Development countries, Korea is the fastest aging country. We aimed to investigate the relationship between changes in quality of life (QOL) and cognitive function in older adults. Method: Data from the Korean Longitudinal Study of Aging collected from 2008 to 2016 were used. In 3453 participants (men: 1943; women: 1541), QOL was measured by three aspects: general, financial, and familial. Changes in QOL status were assessed by four categories: remained poor, worsened, improved, and remained good. The level of cognitive function was measured by the Mini-Mental State Examination score (MMSE, normal range cut-off value: 24 or above). For the statistical analysis, the generalized equation model (GEE) was performed. Results: For all three aspects of QOL measured, participants whose QOL score remained poor were associated with cognitive decline that their odds ratios (OR) were statistically significant (general: OR = 1.33; familial: OR = 1.39; financial: OR = 1.40). For subgroup analysis by gender, the highest OR in men was the financial aspect of QOL (OR = 1.45); in women, the highest OR was the familial aspect of QOL (OR = 1.75). Conclusion: This study showed an association between QOL and cognitive function in a Korean elderly population. Our findings suggest that QOL measurements with a gender-specific approach can be used as a tool to detect cognitive changes in older adults and help prevent or delay cognitive decline.

Sign in / Sign up

Export Citation Format

Share Document